中晚期宫颈癌用奈达铂、顺铂同期放疗效果分析  

Analysis of Concurrent Radiotherapy for Mid-late Cervical Cancer With Nedaplatin and Cisplatin

作　　者：蔡志强[1] 杨继元[1] 苏小岩[1] 万鹏[1] 张文涛[1] 刘珍[1] 张为家[1] CAI Zhiqiang;YANG Jiyuan;SU Xiaoyan;WAN Peng;ZHANG Wentao;LIU Zhen;ZHANG Weijia(Oncology Department,The First People's Hospital of Jingzhou City,Jingzhou Hubei 434000,China)

机构地区：[1]湖北省荆州市第一人民医院肿瘤科,湖北荆州434000

出　　处：《中国继续医学教育》2019年第8期131-134,共4页China Continuing Medical Education

摘　　要：目的分析奈达铂与顺铂同期放疗治疗中晚期宫颈癌的疗效及度患者生存率影响。方法选取2014年4月—2016年9月收治的中晚期宫颈癌患者50例作为研究对象。按照治疗方法,将其分为奈达铂组和顺铂组,对比两组宫颈癌患者的临床疗效、患者生存率、不良反应及治疗前后患者的生活质量评分。结果两组患者的临床疗效对比,差异不具有统计学意义(P> 0.05);顺铂组与奈达铂组同期放疗对比,两组患者治疗半年、1年、2年的生存率对比,差异均无统计学意义(P> 0.05);相对比顺铂组,奈达铂组血小板及白细胞下降发生率高,而食欲不振、恶心发生率低,差异具有统计学意义(P <0.05);肝肾功能损害及放射性肠炎发生率对比,差异无统计学意义(P> 0.05);两组患者生活质量评分对比,奈达铂组评分更高,差异具有统计学意义(P <0.05)。结论在中晚期宫颈癌治疗中应用奈达铂与顺铂同期放疗,两者临床疗效相近,但奈达铂不良反应更少、耐受性及生活质量评分更高。Objective To analyze the effect of concurrent radiotherapy with nedaplatin and cisplatin in the treatment of advanced cervical cancer and the effect of death rate on death. Methods 50 patients with advanced cervical cancer admitted from April 2014 to September 2016 were selected as the study subjects. According to the treatment method, they were divided into nidaplatin group and cisplatin group. The clinical efficacy, survival rate, adverse reactions and quality of life scores of patients with cervical cancer before and after treatment were compared between the two groups. Results There was no significant difference in clinical efficacy between the two groups (P > 0.05). There was no significant difference between cisplatin group and nedaplatin group in the survival rates of 6 months, 1 year and 2 years (P > 0.05). Compared with cisplatin group, the incidence of platelet and leukocyte decrease was higher in nedaplatin group, while the incidence of appetite and nausea was lower in nedaplatin group (P < 0.05). There was no significant difference in the incidence of liver and kidney damage and radiation enteritis (P > 0.05). Compared with the quality of life score of the two groups, the nidaplatin group scored higher, the difference was statistically significant (P < 0.05). Conclusion The combination of nedaplatin and cisplatin in the treatment of advanced cervical cancer, the clinical efficacy of the two is similar, but nedaplatin has fewer adverse reactions, higher tolerance and quality of life.

关 键 词：奈达铂 顺铂 同期放疗 中晚期宫颈癌 疗效 患者生存率 

分 类 号：R737[医药卫生—肿瘤]